Liu W, Liu Y, Ma F, et al. - This retrospective study was conducted to assess if and how anti-PD-1 inhibitor-induced immune-related adverse events (irAEs) are influenced by inflammation-related peripheral blood markers, including neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) levels. They included 150 patients suffering from stage III–IV non-small-cell lung cancer (NSCLC) managed with PD-1 inhibitors at a single center from 2017 to 2020. At least one irAEs was experienced by 57 patients during follow-up, primarily grade 1– 2 (73.68%). The irAEs that most commonly occurred were pruritus, rash, and thyroiditis. Findings showed that an increased risk of severe irAEs was present in relation to levels of NLR, PLR and neutrophil when baseline levels were low. It was inferred that NLR, PLR, and neutrophil (simple and available biomarkers) can be used to aid severe adverse effects prediction in patients with NSCLC managed with anti-PD-1 inhibitors.